Skip to main content
All Posts By

dhadmin1

Coronavirus Vaccine Development Underway by Vault Pharma

By Uncategorized
LOS ANGELES--(BUSINESS WIRE)--An emerging company developing biotechnology invented at UCLA is adapting their approach to address the novel coronavirus, with the goal of adding to the anti-COVID-19 arsenal that follows an initial vaccine. The company, Vault Pharma, is working with UCLA and other universities to advance a vaccine with the potential to treat the virus in addition to protecting against it. Vault Pharma was co-founded by Leonard H. Rome, distinguished professor of biological chemistry and...
Read More

Multiverse Investment Fund Announces Portfolio Company’s Commencement of Clinical Trials to Treat Acute Respiratory Distress Syndrome (ARDS) Caused by Coronavirus (COVID-19)

By Uncategorized

ARDS has been identified as the leading cause of COVID-19-related fatalities; in preclinical studies, Orbsen Therapeutics’ proprietary ORBCEL cellular therapy demonstrated the ability to mitigate the effects of ARDS by improving lung oxygenation, lessening inflammation, reducing edema and decreasing bacterial infection LOS ANGELES, April 15, 2020 (GLOBE NEWSWIRE) — via NetworkWire – Addressing the finding that most fatalities from COVID-19 are caused by the nonreversible development of acute respiratory distress syndrome (ARDS), Multiverse Investment Fund I, LP, a private…

Read More

Vault Pharma Chosen as Finalist at BIO’s 2017 Start-Up Stadium

By Uncategorized

Finalists in Global Competition to Present to Members of Investment and Venture Capitalists Communities Los Angeles, CA: (PRWEB) June 15, 2017 — Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer, Women’s health, and infectious diseases, has been selected as a finalist and will present before an international panel of judges and investors on June 21, 2017, in San Diego at Start-Up Stadium at the BIO International Convention, the world’s largest biotechnology event….

Read More

Vault Pharma Adds Two Experienced Industry Executives to Board of Directors

By Uncategorized

Two new board members have histories of building successful pharma companies. Los Angeles, CA (PRWEB) May 08, 2017 — Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer and infectious diseases, named Michael J. Kamdar, Chief Executive Officer and Director at Molecular Assemblies Inc., and Todd N. Smith, Chief Executive Officer at Novum Pharma, to the company’s Board of Directors. “Mike and Todd add depth, experience and leadership to an already distinguished group…

Read More

Vault Pharma Announces Oliver Foellmer as President and CEO

By Uncategorized

Experienced Biotech Leader To Guide Company As Therapies Enter Clinical Trials (PRWEB) April 27, 2017 — Los Angeles – Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer and infectious diseases, named Oliver Foellmer as President and Chief Executive Officer. Vault Pharma is developing a unique therapeutics platform using the body’s own naturally occurring vault protein particles found abundantly in human cells to activate the immune system against cancer cells, bacteria and viruses….

Read More

Vault Pharma Announces Dr. James Mulé & Dr. Antoni Ribas to Join Scientific Advisory Board

By News

Los Angeles, California – June 22, 2015.    Vault Pharma (VPI) (www.vaulpharma.com), a biotechnology company developing immune therapies for cancer and infectious diseases, announced the addition of two high profile immune oncology experts to its Scientific Advisory Board. James Mulé Ph.D. and Antoni Ribas M.D. Ph.D. will join scientific founder Leonard Rome Ph.D. and Paul Wender Ph.D. in advising the company on research and development efforts. “This is a tremendous step for VPI,” said Michael…

Read More

Vault Pharma Announces Granting of U.S. Cancer Immune Therapy Patent Supporting ImmunOncologyTM Programs and Treatment for Lung and Metastatic Cancers

By News

Los Angeles, California – February 6, 2015.    Vault Pharma announced that it has been granted a U.S. patent titled Vault Complexes for Cytokine Delivery. This patent supports Vault Pharma’s ImmunOncologyTM portfolio, a group of new medicines activating specific responses of the immune system to destroy cancer. Vault Pharma’s lead cancer drug, VPI-101, is a cytokine-based immune stimulant that is delivered by a novel human protein nanoparticle, called a vault. VPI-101 is on schedule to…

Read More

Vault Pharma Announces Initiation of GLP/GMP Manufacturing Collaboration with Protein Sciences Corporation

By News

Los Angeles, California – January 19, 2015.    Vault Pharma announced that its clinical manufacturing collaboration with Protein Sciences Corporation has been initiated to produce its lead immunotherapeutic against lung cancer. The collaboration is for the production of Vault Pharma’s lead cancer drug, VPI-101. VPI-101 is a cytokine-based immune stimulant that is delivered by a novel human protein nanoparticle, called a vault. Discovered at UCLA, vaults are being commercialized for a number of therapeutic indications…

Read More